| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3057242 | A | Prodrug conversion in Homo sapiens (human) liver cytosol assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid formation | Homo sapiens | 1 | ALA3045872 | tissue-based format | Scientific Literature | |
| 2. | ALA3538311 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presence of pargyline by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 3. | ALA3538312 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presence of allopurinol by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 4. | ALA3538560 | A | Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 5. | ALA3538561 | A | Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation per mg protein after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 6. | ALA3538562 | A | Ratio of Vmax to Km for drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation per mg protein after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | assay format | Scientific Literature | |
| 7. | ALA3538563 | A | Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 8. | ALA3538564 | A | Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation per mg protein after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 9. | ALA3538565 | A | Ratio of Vmax to Km for drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation per mg protein after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | assay format | Scientific Literature | |
| 10. | ALA3538857 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM after 60 mins in presence of co-incubation with ritonavir by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 11. | ALA3538858 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM after 60 mins in presence of pre-incubation with ritonavir by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 12. | ALA3538859 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presence of flufenamic acid by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 13. | ALA3538860 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM after 60 mins in presence of AKR inhibitor diazepam by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 14. | ALA3538861 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM after 60 mins in presence of AKR inhibitor ibuprofen by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 15. | ALA3538862 | A | Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presence of BNPP by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | assay format | Scientific Literature | |
| 16. | ALA3538868 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534129 assessed as 100 uM flufenamic acid-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 17. | ALA3538869 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534129 assessed as 100 uM diazepam-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 18. | ALA3538870 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534129 assessed as 1 mM ibuprofen-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 19. | ALA3538871 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534128 assessed as 1 mM BNPP-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 20. | ALA3538872 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534129 assessed as 1 mM BNPP-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!